The therapeutic potential of nicotine and nicotinic agonists for weight control

Bibliography

• BRAY GA: Obesity: a time bomb to be defused. Lancet (1998) 352:160–161.
   PubMed Web of Science ®Google Scholar
• BJORNTORP P: Obesity. Lancet (1997) 350:423–426.
   PubMedGoogle Scholar
• ANATE M, OLATINWO AW, OMESINA AP: Obesity - an overview. West Afr. J. Med. (1998) 17:248–254.
   PubMedGoogle Scholar
• LAMARCHE B: Abdominal obesity and its metabolic complications: implications for the risk of ischaemic heart disease. Coron. Artery Dis. (1998) 9:473–481.
   PubMed Web of Science ®Google Scholar
• LARGE V, ARNER P: Regulation of lipolysis in humans. Pathophysiological modulation in obesity, diabetes, and hyperlipidaemia. Diabet. Metab. (1998) 24:409–418.
   Web of Science ®Google Scholar
• PATTON GC, SELZER R, COFFEY C et al: Onset of adoles-cent eating disorders: population based cohort study over 3 years. BMJ (1999) 318:765–768.
   PubMed Web of Science ®Google Scholar
• KORDIK CP, REITZ AB: Pharmacological treatment of obesity: therapeutic strategies. J. Med. Chem. (1999) 42:181–201.
   PubMed Web of Science ®Google Scholar
• KOLANOWSKI J: A risk-benefit assessment of anti-obesity drugs. Drug Sal (1999) 20:119–131.
   PubMed Web of Science ®Google Scholar
• HIRSCH J: The treatment of obesity with drugs. Am. J. Nutr. (1998) 67:2–4.
   PubMed Web of Science ®Google Scholar
• ATKINSON RL: Use of drugs in the treatment of obesity. Annu. Rev. Nutr. (1997) 17:383–403.
   PubMed Web of Science ®Google Scholar
• HAYS JT, DALE LC, HURT RD, CROGHAN IT: Trends in smoking-related diseases. Why smoking cessation is still the best medicine. Postgrad. Med. (1998) 104:56–62.
   Google Scholar
• CINCIRIPINI PM, MCCLURE JB: Smoking cessation: recent developments in behavioral and pharma-cologic interventions. Oncology (1998) 12:249–256.
   PubMed Web of Science ®Google Scholar
• LAM TH, HE Y, LI LS et al.: Mortality attributable to cigarette smoking in China. JAMA (1997) 278:1505–1508.
   PubMed Web of Science ®Google Scholar
• SWAN GE, JACK LM, WARD MM: Subgroups of smokers with different success rates after use of transdermal nicotine. Addiction (1997) 92:207–217.
   PubMed Web of Science ®Google Scholar
• SETTER SM, JOHNSON MD: Transdermal nicotine replacement smoking cessation therapy. Ann Pharma-cother. (1998) 32:264–266.
   PubMed Web of Science ®Google Scholar
• DAUGHTON D, SUSMAN J, SITORIUS M et al.:Transdermal nicotine therapy and primary care. Importance of counseling, demographic, and partici-pant selection factors on 1-year quit rates. The Nebraska Primary Practice Smoking Cessation Trial Group. Arch. Fain. Med. (1998) 7:425–430.
   Google Scholar
• JORENBY DE, HATSUKAMI DK, SMITH SS et al.: Charac-terization of tobacco withdrawal symptoms: transdermal nicotine reduces hunger and weight gain. Psychopharmacology (1996) 128:130–138.
   PubMed Web of Science ®Google Scholar
• HUGHES JR, HATSUKAMI DK: Effects of three doses of transdermal nicotine on post-cessation eating, hunger and weight. J. Subst. Abuse (1997) 9:151–159.
   PubMedGoogle Scholar
• DALE LC, SCHROEDER DR, WOLTER TD et al.: Weight change after smoking cessation using variable doses of transdermal nicotine replacement. J. Gen. Intern. Med. (1998) 13:9–15.
   PubMed Web of Science ®Google Scholar
• HAJEK P, JACKSON P, BELCHER M: Long-term use of nicotine chewing gum. Occurrence, determinants, and effect on weight gain. JAMA (1988) 260:1593–1596.
   Google Scholar
• JORENBY DE et al.: A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. NewEngl.J. Med. (1999) 340:685–691.
   PubMed Web of Science ®Google Scholar
• PINTO BM, BORRELLI B, KING TK et al.: Weight control smoking among sedentary women. Addict. Behav. (1999) 24:75–86.
   PubMed Web of Science ®Google Scholar
• GURWITZ D: Molecular targets for weight control. Drug Disc. Tod. (1998) 3:426.
   Web of Science ®Google Scholar
• LEVIN ED, MORGAN MM, GALVEZ C, ELLISON GD: Chronic nicotine and withdrawal effects on body weight and food and water consumption in female rats. Physiol. Behav. (1987) 39:441–444.
   PubMed Web of Science ®Google Scholar
• MORGAN MM, ELLISON G: Different effects of chronicnicotine treatment regimens on body weight and tolerance in the rat. Psychopharmacology (1987) 91:236–238.
   PubMed Web of Science ®Google Scholar
• WELLMAN PJ, MARMON MM, REICH S, RUDDLE J: Effectsof nicotine on body weight, food intake and brown adipose tissue thermogenesis. Pharmacol. Biochem. Behav. (1986) 24:1605–1609.
   PubMed Web of Science ®Google Scholar
• ERICKSON CK, BYERS KI: Sustained nicotine releasecomparisons in six inbred rat strains. Pharmacol. Biochem. Behav. (1989) 33:63–67.
   PubMed Web of Science ®Google Scholar
• HEINRICHS SC, LAPSANSKY J, BEHAN DP et al.:Corticotropin-releasing factor-binding protein ligand inhibitor blunts excessive weight gain in genetically obese Zucker rats and rats during nicotine withdrawal. Proc. Natl. Acad. Sci. USA (1996) 93:15475–15480.
   PubMed Web of Science ®Google Scholar
• FUNG YK, LAU YS: Receptor mechanisms of nicotine-induced locomotor hyperactivity in chronic nicotine-treated rats. Eur. j Pharmacol. (1988) 152:263–271.
   PubMed Web of Science ®Google Scholar
• BENWELL ME, BALFOUR DJ, KHADRA LF: Studies on theinfluence of nicotine infusions on mesolimbic dopamine and locomotor responses to nicotine. Clin. Investig. (1994) 72:233–239.
   PubMedGoogle Scholar
• GOSHIMA Y, MIYAMAE T, NAKAMURA S et al: Ventraltegmental injection of nicotine induces locomotor activity and L-DOPA release from nucleus accumbens. Eur. J. Pharmacol. (1996) 309:229–233.
   PubMed Web of Science ®Google Scholar
• LOUIS M, CLARKE PB: Effect of ventral tegmental6-hydroxydopamine lesions on the locomotor stimulant action of nicotine in rats. Neuropharmacology (1998) 37:1503–1513.
   PubMed Web of Science ®Google Scholar
• GRADY SR, GRUN EU, MARKS MJ, COLLINS AC: Pharma-cological comparison of transient and persistent [311]dopamine release from mouse striatal synapto-somes and response to chronic L-nicotine treatment. J. Pharmacol. Exp. Ther. (1997) 282:32–43.
   PubMed Web of Science ®Google Scholar
• PIDOPLICHKO VI, DEBIASI M, WILLIAMS JT, DANI JA:Nicotine activates and desensitizes midbrain dopamine neurons. Nature (1997) 390:401–404.
   PubMed Web of Science ®Google Scholar
• COSCINA DV, NOBREGA JN: 6-Hydroxydopamine-induced blockade of hypothalamic obesity: critical role of brain dopamine-norepinephrine interaction. Prog. Neuropsychopharmacol Biol. Psychiat. (1982) 6:369–372.
   PubMed Web of Science ®Google Scholar
• NOBREGA JN, COSCINA DV: Dopamine-norepinephrine interactions in the development of hyperphagia and obesity following medial hypotha-lamic lesions. Pharmacol Biochem. Behav. (1986) 25:401–409.
   PubMed Web of Science ®Google Scholar
• COMINGS DE, FLANAGAN SD, DIETZ G et al.: The dopamine D2 receptor (DRD2) as a major gene in obesity and height. Biochem. Med. Metab. Biol (1993) 50:176–185.
   PubMedGoogle Scholar
• COMINGS DE, GADE R, MACMURRAY JP et al.: Geneticvariants of the human obesity (013) gene: association with body mass index in young women, psychiatric symptoms, and interaction with the dopamine D2 receptor (DRD2) gene. Mol Psychiat. (1996) 1:325–335.
   PubMed Web of Science ®Google Scholar
• HAACK DG, BAUMANN RJ, MCKEAN HE et al: Nicotineexposure and Parkinson's disease. Am. J. Epidemiol. (1981) 114:191–200.
   PubMed Web of Science ®Google Scholar
• FAGERSTROM KO, POMERLEAU 0, GIORDANI B, STELSON F: Nicotine may relieve symptoms of Parkin-son's disease. Psychopharmacology (1994) 116:117–119.
   PubMed Web of Science ®Google Scholar
• HELLENBRAND W, SEIDLER A, ROBRA BP et al.: Smoking and Parkinson's disease: a case-control study in Germany. Int. J. Epidemiol. (1997) 26:328–339.
   PubMed Web of Science ®Google Scholar
• TZOURIO C, ROCCA WA, BRETELER MM et al.: Smoking and Parkinson's disease. An age-dependent risk effect? The EUROPARKINSON Study Group. Neurology (1997) 49:1267–1272.
   Google Scholar
• GORELL JM, RYBICKI BA, JOHNSON CC, PETERSON EL:Smoking and Parkinson's disease: a dose-response relationship. Neurology (1999) 52:115–119.
   PubMed Web of Science ®Google Scholar
• GERACIOTI TD JR, WEST SA, BAKER DG et al.: Low CSF concentration of a dopamine metabolite in tobacco smokers. Am. J. Psychiat. (1999) 156:130–132.
   PubMed Web of Science ®Google Scholar
• ZIV I, MELAMED E, NARDI N et al.: Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons - a possible novel pathogenetic mechanism in Parkinson's disease. Neurosci. Lett. (1994) 170:136–140.
   PubMed Web of Science ®Google Scholar
• SIMANTOV R, BLINDER E, RATOVITSKI T et al.: Dopamine-induced apoptosis in human neuronal cells: inhibition by nucleic acids antisense to the dopamine transporter. Neuroscience (1996) 74:39–50.
   PubMed Web of Science ®Google Scholar
• OFFEN D, ZIV I, PANET H et al.: Dopamine-induced apoptosis is inhibited in PC12 cells expressing Bc1-2. Cell Mol Neurobiol. (1997) 17:289–304.
   PubMed Web of Science ®Google Scholar
• LUO Y, UMEGAKI H, WANG X et al.: Dopamine induces apoptosis through an oxidation-involved SAPK/JNK activation pathway../. Biol. Chem. (1998) 273:3756–3764.
   PubMed Web of Science ®Google Scholar
• MCLAUGHLIN BA, NELSON D, ERECINSKA M, CHESSELET MF: Toxicity of dopamine to striatal neurons in vitro and potentiation of cell death by a mitochondrial inhibitor. J. Neurochem. (1998) 70:2406–2415.
   PubMed Web of Science ®Google Scholar
• HATTORI A, LUO Y, UMEGAKI H et al.: Intrastriatal injection of dopamine results in DNA damage and apoptosis in rats. Neuroreport (1998) 9:2569–2572.
   PubMed Web of Science ®Google Scholar
• LIU X, PERUSSE F, BUKOWIECKI LJ: Mechanisms of the antidiabetic effects of the beta 3-adrenergic agonist CL-316243 in obese Zucker-ZDF rats. Am. J. Physiol (1998) 274:R1212–1219.
   PubMed Web of Science ®Google Scholar
• FLETCHER DS, CANDELORE MR, GRUJIC D et al.: Beta-3 adrenergic receptor agonists cause an increase in gastrointestinal transit time in wild-type mice, but not in mice lacking the beta-3 adrenergic receptor. J. Pharmacol. Exp. Ther. (1998) 287:720–724.
   PubMed Web of Science ®Google Scholar
• PARMEE ER, OK HO, CANDELORE MR et al.: Discovery of L-755,507: a subnanomolar human beta 3 adrenergic receptor agonist. Bioorg. Med. Chem. Lett. (1998) 8:1107–1112.
   PubMed Web of Science ®Google Scholar
• NAYLOR EM, COLANDREA VJ, CANDELORE MR et al.:3-Pyridylethanolamines: potent and selective human beta 3 adrenergic receptor agonists. Bioorg. Med. Chem. Lett. (1998) 8:3087–3092.
   PubMed Web of Science ®Google Scholar
• YOSHITOMI H, YAMAZAKI K, ABE S, TANAKA I: Differen-tial regulation of mouse uncoupling proteins among brown adipose tissue, white adipose tissue, and skeletal muscle in chronic beta 3 adrenergic receptor agonist treatment. Biochem. Biophys. Res. Commun. (1998) 253:85–91.
   PubMed Web of Science ®Google Scholar
• VERDY M: Effect of caffeine, nicotine and ethanol on lipolysis in human adipose tissue. Rev. Can. Biol. (1967) 26:179–184.
   PubMedGoogle Scholar
• ILEBEKK A, MILLER NE, MJOS OD: Effects of nicotine andinhalation of cigarette smoke on total body oxygen consumption in dogs. Scand. J. Clin. Lab. Invest. (1975) 35:67–72.
   PubMed Web of Science ®Google Scholar
• MJOS OD: Lipid effects of smoking. Am. Heart. J. (1988)115:272–275.
   PubMed Web of Science ®Google Scholar
• ANDERSSON K, ENEROTH P, ARNER P: Changes in circulating lipid and carbohydrate metabolites following systemic nicotine treatment in healthy men. Int. J. Obes. Relat. Metab. Disord. (1993) 17:675–680.
   PubMed Web of Science ®Google Scholar
• ANDERSSON K, ARNER P: Cholinoceptor-mediated effects on glycerol output from human adipose tissue using in situ microdialysis. Br. J. Pharmacol. (1995) 115:1155–1162.
   PubMed Web of Science ®Google Scholar
• SZTALRYD C, HAMILTON J, HORWITZ BA et al: Altera-tions of lipolysis and lipoprotein lipase in chronically nicotine-treated rats. Am]. Physiol. (1996) 270:E215–223.
   PubMed Web of Science ®Google Scholar
• LUPIEN JR, BRAY GA: Nicotine increases thermogenesis in brown adipose tissue in rats. Pharmacol. Biochem. Behav. (1988) 29:33–37.
   PubMed Web of Science ®Google Scholar
• YOSHIDA T, YOSHIOKA K, HIRAOKA N, KONDO M: Effect of nicotine on norepinephrine turnover and thermogenesis in brown adipose tissue and metabolic rate in MSG obese mice. J. Nutr. Sci. Vitaminol. (Tokyo) (1990) 36:123–130.
   PubMed Web of Science ®Google Scholar
• FRIEDMAN JM, HALAAS JL: Leptin and the regulation of body weight in mammals. Nature (1998) 395:763–770.
   PubMed Web of Science ®Google Scholar
• PROLO P, WONG ML, LICINIO J: Leptin. Int. J. Biochem. Cell Biol. (1998) 30:1285–1290.
   PubMed Web of Science ®Google Scholar
• HODGE AM WESTERMAN RA, DE COURTEN MP et al.: Is leptin sensitivity the link between smoking cessation and weight gain? Int. J. Obes. Relat. Metab. Disord. (1997) 21:50–53.
   PubMed Web of Science ®Google Scholar
• MANTZOROS CS, LIOLIOS AD, TRITOS NA et al.:Circulating insulin concentrations, smoking, and alcohol intake are important independent predictors of leptin in young healthy men. Obes. Res. (1998) 6:179–186.
   PubMedGoogle Scholar
• DONAHUE RP, ZIMMET P, BEAN JA et al.: Cigarettesmoking, alcohol use, and physical activity in relation to serum leptin levels in a multiethnic population: The Miami Community Health Study. Ann. Epidemiol. (1999) 9:108–113.
   PubMed Web of Science ®Google Scholar
• ELIASSON B, SMITH U: Leptin levels in smokers andlong-term users of nicotine gum. Eur. J. Clin. Invest. (1999) 29:145–152.
   PubMed Web of Science ®Google Scholar
• GERALD C, WALKER MW, CRISCIONE L et al: A receptorsubtype involved in neuropeptide-Y-induced food intake. Nature (1996) 382:168–171.
   PubMed Web of Science ®Google Scholar
• WOLDBYE DP, LARSEN PJ: The how and Y of eating. Nature Med. (1998) 4:671–672.
   PubMed Web of Science ®Google Scholar
• STEPHENS TW: Fat regulation. Life without neuropep-tide Y. Nature (1996) 381:377–378.
   Google Scholar
• ERICKSON JC: Attenuation of the obesity syndrome of ob/ob mice by the loss of neuropeptide Y. Science (1996) 274:1704–1707.
   PubMed Web of Science ®Google Scholar
• KALRA SP, HORVATH TL: Neuroendocrine interactionsbetween galanin, opioids, and neuropeptide Y in the control of reproduction and appetite. Ann. New York Acad. Sci. (1998) 863:236–240.
   PubMed Web of Science ®Google Scholar
• RIZK NM, LIU LS, ECKEL J: Hypothalamic expression of neuropeptide-Y in the New Zealand obese mouse. Int..) Obes. Relat. Metab. Disord. (1998) 22:1172–1177.
   PubMed Web of Science ®Google Scholar
• FRANKISH HM, DRYDEN S, WANG Q et al.: Nicotine administration reduces neuropeptide Y and neuropeptide Y mRNA concentrations in the rat hypothalamus: NPY may mediate nicotine's effects on energy balance. Brain Res. (1995) 694:139–146.
   PubMed Web of Science ®Google Scholar
• HIREMAGALUR B, SABBAN EL: Nicotine elicits changes in expression of adrenal catecholamine biosynthetic enzymes, neuropeptide Y and immediate early genes by injection but not continuous administration. Brain Res. Mol Brain Res. (1995) 32:109–115.
   PubMedGoogle Scholar
• JAHNG JW, HOUPT TA, JOH TH, WESSEL TC: Expression of catecholamine-synthesizing enzymes, peptidylglycine alpha-amidating monooxygenase, and neuropeptide Y mRNA in the rat adrenal medulla after acute systemic nicotine. J. Mol Neurosci. (1997) 8:45–52.
   PubMed Web of Science ®Google Scholar
• OBUCHOWICZ E, TURCHAN J: Influence of typical andatypical antipsychotics on neuropeptide Y-like immunoreactivity and NPY mRNA expression in rat striatum. Neuropeptides (1998) 32:473–480.
   PubMed Web of Science ®Google Scholar
• OBUCHOWICZ E, TURCHAN J: Effects of acute or long-term treatment with chlorpromazine, haloperidol or sulpiride on neuropeptide Y-like immunoreactivity concentrations in the nucleus accumbens of rat. Eur. Neuropsychopharmacol (1999) 9:51–59.
   PubMed Web of Science ®Google Scholar
• MIYAKE M, IGUCHI K, OKAMURA H et al: Effect of haloperidol on immunoreactive neuropeptide Y in rat cerebral cortex and basal ganglia. Brain Res. Bull. (1990) 25:263–269.
   PubMed Web of Science ®Google Scholar
• DRESCHER VS, CHEN HL, ROMSOS DR: Corticotropin-releasing hormone decreases feeding, oxygen consumption and activity of genetically obese (ob/ob) and lean mice. J. Nutr. (1994) 124:524–530.
   PubMed Web of Science ®Google Scholar
• KALRA SP, DUBE MG, PU S: Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr. Rev. (1999) 20:68–100.
   PubMed Web of Science ®Google Scholar
• JANG M, ROMSOS DR: Neuropeptide Y and corticotropin-releasing hormone concentrations within specific hypothalamic regions of lean but not ob/ob mice respond to food-deprivation and refeeding. j Nutr. (1998) 128:2520–2525.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ MW, SEELEY RJ, CAMPFIELD LA et al.: Identi-fication of targets of leptin action in rat hypothalamus. Clin. Invest. (1996) 98:1101–1106.
   Google Scholar
• UEHARA Y, SHIMIZU H, OHTANI K et al.: Hypothalamic corticotropin-releasing hormone is a mediator of the anorexigenic effect of leptin. Diabetes (1998) 47:890–893.
   PubMed Web of Science ®Google Scholar
• VALENTINE JD, MATTA SG, SHARP BM: Nicotine-inducedcFos expression in the hypothalamic paraventricular nucleus is dependent on brainstem effects: correla-tions with cFos in catecholaminergic and noncatecho-laminergic neurons in the nucleus tractus solitarius. Endocrinology (1996) 137:622–630.
   PubMed Web of Science ®Google Scholar
• MATTA SG, VALENTINE JD, SHARP BM: Nicotinic activa- tion of CRH neurons in extrahypothalamic regions of the rat brain. Endocrine (1997) 7:245–253.
   PubMed Web of Science ®Google Scholar
• CALOGERO AE, GALLUCCI WT, BERNARDINI R et al.: Effect of cholinergic agonists and antagonists on rat hypothalamic corticotropin-releasing hormone secretion in vitro. Neuroendocrinology (1988) 47:303–308.
   PubMed Web of Science ®Google Scholar
• VENIHAKI M, AIN K, DERMITZAKI E et al.: KAT45, a noradrenergic human pheochromocytoma cell line producing corticotropin-releasing hormone. Endocri-nology (1998) 139:713–722.
   PubMed Web of Science ®Google Scholar
• KUNZE U, SCHOBERBERGER R, SCHMEISER-RIEDER A et al.: Alternative nicotine delivery systems (ANDS)-public health-aspects. Wien. KIM. Wochenschr. 110:811–816.
   Google Scholar
• BLONDAL T, GUDMUNDSSON LJ, OLAFSDOTTIR I et al.: Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up. BMJ (1999) 318:285–288.
   PubMed Web of Science ®Google Scholar
• DAUGHTON DM, FORTMANN SP, GLOVER ED et al: The smoking cessation efficacy of varying doses of nicotine patch delivery systems 4 to 5 years post-quit day. Prey. Med. (1999) 28:113–118.
   PubMed Web of Science ®Google Scholar
• BERRIDGE V: Histories of harm reduction: illicit drugs, tobacco, and nicotine. Subst. Use Misuse. (1999) 34:35–47.
   PubMed Web of Science ®Google Scholar
• PICCIOTTO MR: Common aspects of the action of nicotine and other drugs of abuse. DrugAkohol Depend. (1998) 51:165–172.
   PubMed Web of Science ®Google Scholar
• EPPING-JORDAN MP, WATKINS SS, KOOB GF, MARKOU A: Dramatic decreases in brain reward function during nicotine withdrawal. Nature (1998) 393:76–79.
   PubMed Web of Science ®Google Scholar
• REID MS, MICKALIAN JD, DELUCCHI KL, BERGER SP: A nicotine antagonist, mecamylamine, reduces cue-induced cocaine craving in cocaine-dependent subjects. Neuropsychopharmacology (1999) 20:297–307.
   PubMed Web of Science ®Google Scholar
• WANNAMETHEE SG, SHAPER AG, WHINCUP PH, WALKER M: Smoking cessation and the risk of stroke in middle-aged men. JAMA (1995) 274:155–160.
   PubMed Web of Science ®Google Scholar
• HAHEIM LL,HOLME I, HJERMANN I, LEREN P: Smoking habits and risk of fatal stroke: 18 years follow up of the Oslo Study. J. Epidemiol. Commun. Health. (1996) 50:621–624.
   PubMed Web of Science ®Google Scholar
• SHINTON R: Lifelong exposures and the potential for stroke prevention: the contribution of cigarette smoking, exercise, and body fat. J. Epidemiol. Commun. Health (1997) 51:138–143.
   PubMed Web of Science ®Google Scholar
• ALDOORI MI, RAHMAN SH: Smoking and stroke: a causative role. Heavy smokers with hypertension benefit most from stopping. BMJ (1998) 317:962–963.
   Google Scholar
• ZIDOVETZKI R, CHEN P, FISHER M et al.: Nicotine increases plasminogen activator inhibitor-1 produc-tion by human brain endothelial cells via protein kinase C-associated pathway. Stroke (1999) 30:651–655.
   PubMed Web of Science ®Google Scholar
• GENG Y, SAVAGE SM, JOHNSON LJ et al.: Effects of nicotine on the immune response. I. Chronic exposure to nicotine impairs antigen receptor- mediated signal transduction in lymphocytes. Toxicol Appl. Pharmacol (1995) 135:268–278.
   Google Scholar
• GENG Y, SAVAGE SM, RAZANAI-BOROUJERDI S, SOPORI ML: Effects of nicotine on the immune response. II. Chronic nicotine treatment induces T cell anergy. Immunol. (1996) 156:2384–2390.
   Google Scholar
• MCALLISTER-SISTILLI CG, CAGGIULA AR, KNOPF S et al.: The effects of nicotine on the immune system. Psychoneuroendocrinology (1998) 23:175–187.
   PubMed Web of Science ®Google Scholar
• SOPORI ML, KOZAK W, SAVAGE SM et al.: Effect of nicotine on the immune system: possible regulation of immune responses by central and peripheral mechanisms. Psychoneuroendocrinology (1998) 23:189–204.
   PubMed Web of Science ®Google Scholar
• MELLON RD, BAYER BM: The effects of morphine, nicotine and epibatidine on lymphocyte activity and hypothalamic-pituitary-adrenal axis responses. J. Pharmacol. Exp. Ther. (1999) 288:635–642.
   PubMed Web of Science ®Google Scholar
• HOLLADAY MW, DART MJ, LYNCH JK: Neuronal nicotinic acetylcholine receptors as targets for drug discovery. J. Med. Chem. (1997) 40:4169–4194.
   PubMed Web of Science ®Google Scholar
• BARRANTES FJ: The acetylcholine receptor ligand-gated channel as a molecular target of disease and therapeutic agents. Neurochem. Res. (1997) 22:391–400.
   PubMed Web of Science ®Google Scholar
• COLQUHOUN LM, PATRICK JW: Pharmacology of neuronal nicotinic acetylcholine receptor subtypes. Adv. Pharmacol. (1997) 39:191–220.
   PubMedGoogle Scholar
• BRIONI JD, DECKER MW, SULLIVAN JP, ARNERIC SP: The pharmacology of (-)-nicotine and novel cholinergic channel modulators. Adv. Pharmacol. (1997) 37:153–214.
   PubMedGoogle Scholar
• LLOYD GK, MENZAGHI F, BONTEMPI B et al.: The potential of subtype-selective neuronal nicotinic acetylcholine receptor agonists as therapeutic agents. Life Sci. (1998) 62:1601–1606.
   PubMed Web of Science ®Google Scholar
• SIHVER W, GILLBERG PG, NORDBERG A: Laminar distri-bution of nicotinic receptor subtypes in human cerebral cortex as determined by [311]0nicotine, ellicytisine and rlilepibatidine in vitro autoradiog-raphy. Neuroscience (1998) 85:1121–1133.
   PubMedGoogle Scholar
• GIACOBINI E: New trends in cholinergic therapy for Alzheimer's disease: nicotinic agonists or cholines-terase inhibitors? Prog. Brain Res. (1996) 109:311–323.
   Web of Science ®Google Scholar
• BALDINGER SL et al.: Nicotine therapy in patients with Alzheimer's disease. Ann. Pharmacother. (1995) 29:314–315.
   PubMed Web of Science ®Google Scholar
• JAMES JR et al.: Genetic and environmental aspects of the role of nicotinic receptors in neurodegenerative disorders: emphasis on Alzheimer's disease and Parkinson's disease. Behav. Genet. (1995) 25:149–159.
   PubMed Web of Science ®Google Scholar
• KEM WR: Alzheimer's drug design based upon an invertebrate toxin (anabaseine) which is a potent nicotinic receptor agonist. Invert. Neurosci. (1997) 3:251–259.
   PubMedGoogle Scholar
• PARKS RW, BECKER RE, RIPPEY RF et al. Increased regional cerebral glucose metabolism and semantic memory performance in Alzheimer's disease: a pilot double blind transdermal nicotine positron emission tomography study. Neuropsychol. Rev. (1996) 6:61–79.
   PubMed Web of Science ®Google Scholar
• SNAEDAL J et al.: The effects of nicotine in dermal plaster on cognitive functions in patients with Alzheimer's disease. Dementia (1996) 7:47–52.
   PubMedGoogle Scholar
• ARNERIC SP, SULLIVAN JP, DECKER MW et al.: Potential treatment of Alzheimer's disease using cholinergic channel activators (ChCAs) with cognitive enhance-ment, amdolytic-like, and cytoprotective properties. Alzheimer Dis. Assoc. Disord. (1995) 9\(Suppl. 2):50–61.
   Google Scholar
• PRENDERGAST MA, TERRY AV JR, JACKSON WJ et al: Improvement in accuracy of delayed recall in aged and non-aged, mature monkeys after intramuscular or transdermal administration of the CNS nicotinic receptor agonist ABT-418. Psychopharmacology (1997) 130:276–284.
   PubMed Web of Science ®Google Scholar
• WILSON AL, LANGLEY LK, MONLEY J et al.: Nicotine patches in Alzheimer's disease: pilot study on learning, memory, and safety. Pharmacol. Biochem. Behav. (1995) 51:509–514.
   PubMed Web of Science ®Google Scholar
• CONNERS CK, LEVIN ED, SPARROW E et al.: Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD). PsychopharmacoL Bull. (1996) 32:67–73.
   PubMed Web of Science ®Google Scholar
• GARLAND EJ. Pharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices and caveats. J. PsychopharmacoL (1998) 12:385–395.
   PubMed Web of Science ®Google Scholar
• MOSS DE, MANDERSCHEID PZ, MONTGOMERY SP et al: Nicotine and cannabinoids as adjuncts to neuroleptics in the treatment of Tourette syndrome and other motor disorders. Life Sci. (1989) 44:1521–1525.
   PubMed Web of Science ®Google Scholar
• SANBERG PR, SILVER AA, SHYTLE RD et al.: Nicotine for the treatment of Tourette's syndrome. Pharmacol Ther. (1997) 74:21–25.
   PubMed Web of Science ®Google Scholar
• DURSUN SM, REVELEY MA: Differential effects of transdermal nicotine on microstructured analyses of tics in Tourette's syndrome: an open study. Psycho]. Med. (1997) 27:483–487.
   PubMed Web of Science ®Google Scholar
• THOMAS GA, RHODES J, GREEN JT: Inflammatory bowel disease and smoking - a review. Am. J. Gastroenterol. (1998) 93:144–149.
   PubMed Web of Science ®Google Scholar
• GUSLANDI M, TITTOBELLO A: Outcome of ulcerative colitis after treatment with transdermal nicotine. Eur. Gastroenterol Hepatol. (1998) 10:513–515.
   PubMed Web of Science ®Google Scholar
• ELIAKIM R, KARMELI F, RACHMILEWITZ D et al.: Effect of chronic nicotine administration on trinitrobenzene sulphonic acid-induced colitis. Eur. J. Gastroenterol. Hepatol. (1998) 10:1013–1019.
   PubMed Web of Science ®Google Scholar
• DAMAJ MI, PATRICK GS, CREASY KR, MARTIN BR: Pharmacology of lobeline, a nicotinic receptor ligand. J. Pharmacol Exp. Ther. (1997) 282:410–419.
   PubMed Web of Science ®Google Scholar
• TERRY AV JR, WILLIAMSON R, GATTU M et al Lobeline and structurally simplified analogs exhibit differential agonist activity and sensitivity to antagonist blockade when compared to nicotine. Neuropharmacology (1998) 37:93–102.
   PubMed Web of Science ®Google Scholar
• TENG L, CROOKS PA, SONSALLA PK, DWOSKIN LP: Lobeline and nicotine evoke [311]overflow from rat striatal slices preloaded with [311]dopamine: differen-tial inhibition of synaptosomal and vesicular [311]dopamine uptake. J. Pharmacol Exp. Ther. (1997) 280:1432–1444.
   PubMed Web of Science ®Google Scholar
• PABREZA LA, DHAWAN S, KELLAR KJ: [311]cytisine binding to nicotinic cholinergic receptors in brain. Mol. Pharmacol. (1991) 39:9–12.
   PubMed Web of Science ®Google Scholar
• PAPKE RL, HEINEMANN SF: Partial agonist properties of cytisine on neuronal nicotinic receptors containing the beta 2 subunit. Mol. Pharmacol. (1994) 45:142–149.
   PubMed Web of Science ®Google Scholar
• WENGER BW, BRYANT DL, BOYD RT, MCKAY DB: Evidence for spare nicotinic acetylcholine receptors and a beta 4 subunit in bovine adrenal chromaffin cells: studies using bromoacetylcholine, epibatidine, cytisine and mAb35. J. Pharmacol. Exp. Ther. (1997) 281:905–913.
   PubMed Web of Science ®Google Scholar
• QIAN C, LI T, SHEN TY, LIBERTINE-GARAHAN L et al.: Epibatidine is a nicotinic analgesic. Eur. J. Pharmacol (1993) 250:R13–14.
   PubMed Web of Science ®Google Scholar
• PRINCE RJ, SINE SM: Epibatidine activates muscle acetylcholine receptors with unique site selectivity. Biophys. J. (1998) 75:1817–1827.
   PubMed Web of Science ®Google Scholar
• SEERDEN JP, TULP MT, SCHEEREN HW, KRUSE CG: Synthesis and structure-activity data of some new epibatidine analogues. Bioorg. Med. Chem. (1998) 6:2103–2110.
   PubMed Web of Science ®Google Scholar
• HORTI AG, SCHEFFEL U, KIMES AS et al.: Synthesis and evaluation of N-[11C]methylated analogues of epibati-dine as tracers for positron emission tomographic studies of nicotinic acetylcholine receptors. J. Med. Chem. (1998) 41:4199–4206.
   PubMed Web of Science ®Google Scholar
• NANRI M, MIYAKE H, MURAKAMI Y et al.: GTS-21, a nicotinic agonist, attenuates multiple infarctions and cognitive deficit caused by permanent occlusion of bilateral common carotid arteries in rats. Jpn. J. Pharmacol. (1998) 78:463–469.
   PubMedGoogle Scholar
• MEYER EM, KURYATOV A, GERZANICH V et al. Analysis of 3(4-hydroxy, 2-Methoxybenzylidenejanabaseine selectivity and activity at human and rat alpha-7 nicotinic receptors. J. Pharmacol. Exp. Ther. (1998) 287:918–925.
   PubMed Web of Science ®Google Scholar
• PRENDERGAST MA, JACKSON WJ, TERRY AV JR et al.: Central nicotinic receptor agonists ABT-418, ABT-089, and (-)y-nicotine reduce distractibility in adult monkeys. Psychopharmacology (1998) 136:50–58.
   Google Scholar
• PAPKE RL, THINSCHMIDT JS, MOULTON BA et al: Activa-tion and inhibition of rat neuronal nicotinic receptors by ABT-418. Br. J. Pharmacol (1997) 120:429–438.
   PubMed Web of Science ®Google Scholar
• VERNIER JM, HOLSENBACK H, COSFORD ND et al.: Conformationally restricted analogues of nicotine and anabasine. Bioorg. Med. Chem. Lett. (1998) 8:2173–2178.
   PubMed Web of Science ®Google Scholar
• UN NH, GUNN DE, LI Y et al.: Synthesis and structure-activity relationships of pyridine-modified analogs of 342-((S)-pyrrolidinyfimethoxylpyridine, A-84543, a potent nicotinic acetylcholine receptor agonist. Bioorg. Med. Chem. Lett. (1998) 8:249–254.
   PubMed Web of Science ®Google Scholar
• BECKETT AH, TRIGGS EJ: Determination of nicotine and its metabolite, cotinine, in urine by gas chroma-tography. Nature (1966) 211:1415–1417.
   PubMed Web of Science ®Google Scholar
• CROOKS PA, LI M, DWOSKIN LP: Metabolites of nicotine in rat brain after peripheral nicotine administration. Cotinine, nornicotine, and norcotinine. Drug Metab. Dispos. (1997) 25:47–54.
   PubMed Web of Science ®Google Scholar
• DWOSKIN LP, TENG L, BUXTON ST, CROOKS PA: (5)- -Cotinine, the major brain metabolite of nicotine, stimulates nicotinic receptors to evoke [311]dopamine release from rat striatal slices in a calcium-dependent manner. J. Pharmacol Exp. Ther. (1999) 288:905–911.
   PubMed Web of Science ®Google Scholar
• DE SCHEPPER PJ, VAN HECKEN A, DAENENS P, VAN ROSSUM JM. Kinetics of cotinine after oral and intrave-nous administration to man. Eur. J. Clin. Pharmacol. (1987) 31:583–588.
   PubMed Web of Science ®Google Scholar
• CROOKS PA, DWOSKIN LP. Contribution of CNS nicotine metabolites to the neuropharmacological effects of nicotine and tobacco smoking. Biochem. Pharmacol. (1997) 54:743–753.
   PubMed Web of Science ®Google Scholar
• NAGLE DL, MCGRAIL SH, VITALE J et al.: The mahogany protein is a receptor involved in suppression of obesity. Nature (1999) 398:148–152.
   PubMed Web of Science ®Google Scholar
• GUNN TM, MILLER KA, HE L et al.: The mouse mahogany locus encodes a transmembrane form of human attractin. Nature (1999) 398:152–156.
   PubMedGoogle Scholar
• HINNEY A, SCHMIDT A, NOTTEBOM K et al: Several mutations in the melanocortin-4 receptor gene including a nonsense and a frameshift mutation associated with dominantly inherited obesity in humans. J. Clin. Endocrinol. Metab. (1999) 84:1483–1486.
   PubMed Web of Science ®Google Scholar
• HELLSTROM L, LARGE V, REYNISDOTTIR S et al: The different effects of a Gln27Glu beta 2-adrenoceptor gene polymorphism on obesity in males and in females. J. Intern. Med. (1999) 245:253–259.
   PubMed Web of Science ®Google Scholar
• MORI Y, KIM-MOTOYAMA H, ITO Y et al.: The Gln27Glu beta2-adrenergic receptor variant is associated with obesity due to subcutaneous fat accumulation in japanese men. Biochem. Biophys. Res. Commun. (1999) 258:138–140.
   PubMed Web of Science ®Google Scholar
• BENDER R, JOCKEL KH, TRAUTNER C et al: Effect of age on excess mortality in obesity. JAMA (1999) 281:1498-1504. David Gurwitz National Laboratory for the Genetics of Israeli Populations, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel Tel.: +972 3 640 7611; Fax: +972 3 640 7611; Email: [email protected]
   Google Scholar